News and Events
Galt Pharmaceuticals® Shortens Work Week, Cites Work-Life Balance
August 06, 2021
ATLANTA (August 6, 2021) – When today’s focus of many workplaces is on getting more work done remotely, a company headquartered in Marietta, GA is giving employees one workday back every week in the name of work-life balance.
“We have always had a family-first culture and want to offer our teams more ...
Galt Pharmaceuticals® Acquires Oravig® (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics
December 16, 2020
ATLANTA (December 16, 2020) – Galt Pharmaceuticals® announced the acquisition of a specialty branded product from Fortovia Therapeutics. Effective December 2, 2020, Galt added Oravig®, the first and only orally-dissolving buccal tablet for oral thrush, to its growing portfolio of pharmaceutical assets.
“We are thrilled to add a branded product with distinctive clinical benefits to our growing product portfolio," ...
Galt Relaunches Complete Night Sleep Website
November 17, 2020
Galt Pharmaceuticals® launched a revamped Complete Night Sleep website this November to help educate people about insomnia, its consequences and treatment options.
A sleep questionnaire on the site can help determine if website visitors may be at risk for insomnia. It asks questions such as “Do you frequently ...
Galt Pharmaceuticals® Supports Independent Pharmacist with Liaison
October 27, 2020
Galt Pharmaceuticals® recently expanded its team to include a liaison position for independent pharmacists. A former independent pharmacist himself, Jimmy Fanning, Pharm.D. serves in the new role.
Fanning works with independent pharmacists to identify patients with unmet clinical needs who can benefit from therapeutic intervention. He also works with Pharmacy Development Services – the nation’s premier independent pharmacy business development organization – to identify and assist ...
Galt Launches Orphengesic Forte Website
August 27, 2020
Galt Pharmaceuticals® launched a new website for its newest product, Orphengesic Forte.
The new website launched following approval by the U.S. Food and Drug Administration for Orphengesic Forte on July 8, 2020.
The website will offer patients, caregivers, and healthcare providers a space to learn more about Orphengesic Forte, ...
Opioid-free Pain Med Orphengesic Forte (Galt Pharmaceuticals®) Now Available at U.S. Pharmacies
August 20, 2020
ATLANTA (August 20, 2020) – Galt Pharmaceuticals® announced the commercial availability of Orphengesic® Forte (Orphenadrine Citrate, Aspirin, Caffeine tablets 50mg/770mg/60mg). The non-opioid, non-controlled pain therapy is now available at pharmacies across the U.S. including national chains (e.g. CVS, Walgreens, Wal-Mart) and independent community pharmacies.
Orphengesic Forte was approved ...
Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals® Approved by FDA
July 16, 2020
ATLANTA (July 16, 2020) – Pharmaceutical innovator Galt Pharmaceuticals® announced a new drug approval to offer a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain. On July 8, 2020, the U.S. Food and Drug Administration approved the company’s Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.
“This is a big win in the fight ...
Galt Pharmaceuticals® Expands Team with Medical Science Specialist
June 30, 2020
Galt Pharmaceuticals® welcomed James George, Pharm.D. as the company’s new Medical Science Specialist on July 1. His key responsibilities include educating healthcare professionals on Galt’s product portfolio as well as supporting Galt Phranchisees in the field.
He most recently served as ...
Galt Teams Up with University of Alabama to Provide Experience for Students
May 12, 2020
Galt Pharmaceuticals® teamed up with the University of Alabama to provide real-world experience to six seniors majoring in Information Systems, Statistics & Management Science in the Culverhouse College of Business.
The student group ...
Galt Pharmaceuticals® Introduces New Convenient Package Size for Insomnia Drug
September 24, 2019
ATLANTA (September 24, 2019) – Galt Pharmaceuticals® announced the availability of a new convenient package size of 30 count bottles for Doral 15mg, making the insomnia treatment more accessible to pharmacies and patients across the country.
According to a recent study by the University of Pennsylvania School of Medicine that was reported in Science Daily, one in four Americans experience acute insomnia each year. Although many medications are ...
Galt Pharmaceuticals® Answers the Call for Better Practices in Pain Management with a Non-opioid Therapeutic Alternative
May 29, 2019
Officials with the FDA have given Priority Review designation to an opioid-free pain management treatment from Galt Pharmaceuticals®.
According to the company, its Supplemental Abbreviated New Drug Application for the orphenadrine citrate, aspirin and caffeine combination (Orphengesic Forte), a muscle relaxant pain reliever, was given ...
Innovative Pharma Company Galt Signs 50th Franchise
February 14, 2019
ATLANTA--(BUSINESS WIRE)--The first and only pharmaceutical company to create a unique franchise pharma concept referred to as “phranchising,” Galt Pharmaceuticals® recently signed its 50th territory.
“Our unique model offers the right entrepreneur the opportunity to run their own pharmaceutical company in their local market using a very patient-centric approach to educating healthcare providers,” said Galt CEO and co-founder Barry Patel, Pharm.D.
Validating this transformative model, Atlanta-based Galt brought on ...
Galt Pharmaceuticals® Announces Acquisition of Cutis Health
January 22, 2017
Atlanta, GA: Galt Pharmaceuticals®, LLC announces the acquisition of Cutis Health, LLC. The transaction includes Cutis Health's prescription and non-prescription products as well as its intellectual property and registered marks. Dr. Barry Patel, President & CEO of Galt, stated, “Integrating the Cutis Health brand ...
Mercer College of Pharmacy and Galt Pharmaceuticals® Partners on Industry Fellowship
January 12, 2017
ATLANTA - The College of Pharmacy has established a pharmaceutical industry fellowship with Atlanta-based Galt Pharmaceuticals®. The one-year fellowship is for a pharmacy graduate interested in a career in the pharmaceutical industry.
Cutis Health Announces Acquisition of Doral
April 6, 2016
Atlanta GA: Cutis Health, LLC, a specialty pharmaceutical company based in Atlanta acquires Doral (Quazepam) from Sciecure Pharma, Inc. In addition to the product New Drug Application (NDA), the acquisition includes significant inventory with extended dating. “We are pleased to re-introduce Doral to the ...